Amarin In Play?
Shares of Amarin Corporation plc (Nasdaq: AMRN) are higher early Friday as traders get the memo that the stock is "in play," on likely Vascepa NCE approval and then a potential buyout.
Reports after the close Thursday suggested that NCE approval is 'in the bag.' If this is true, attention will turn to the product launch. The company could go it alone, partner with someone, or sell the entire operation.
Recently, analysts at MKM's Partners have been clamoring that a buyout is likely and could come before the end of the year. They said AstraZeneca (NYSE: AZN) is the most logical suitor, but Pfizer, Bristol Myers, Sanofi and others could also be interested.
Shares of AMRN are up 5 percent today to $12.85.
Disclosure: I am long AMRN, ARNA, ATRS.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.